In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exchange Rates Wipe Out Growth For Abbott’s Established Unit

Executive Summary

Unfavorable foreign-exchange effects eradicated any organic growth for Abbott’s Established Pharmaceuticals unit in the second quarter and first half of 2019.

You may also be interested in...

Abbott’s Established Unit Grows By A Tenth

Abbott’s Established Pharmaceuticals business saw double-digit organic growth in the fourth quarter of 2019 on the back of its “unique branded generic strategy in emerging markets,” particularly in Latin America and Asia.

Abbott Sees Little Impact From Chinese Tenders

Competitive procurement practices for off-patent molecules in China are not affecting Abbott adversely because its local Established Pharmaceuticals portfolio is focused on niche, hard-to-make branded generics.

UK Recommends Against Common Drugs For Chronic Primary Pain

Paracetamol, opioids and non-steroidal anti-inflammatory drugs are among the common medicines that “can do more harm than good” and should not be used for managing chronic primary pain, according to a draft NICE guideline.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts